Revumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial

Simple item page
dc.contributor.authorLoo, S.
dc.contributor.authorIland, H.
dc.contributor.authorTiong, I.S.
dc.contributor.authorWesterman, D.
dc.contributor.authorOthman, J.
dc.contributor.authorMarlton, P.
dc.contributor.authorChua, C.C.
dc.contributor.authorPurtill, D.
dc.contributor.authorRose, H.
dc.contributor.authorFleming, S.
dc.contributor.authorSinghal, D.
dc.contributor.authorEnjeti, A.K.
dc.contributor.authorStevenson, W.S.
dc.contributor.authorNg, T.F.
dc.contributor.authorDerek, M.
dc.contributor.authorVaughan, L.
dc.contributor.authorGasiorowski, R.
dc.contributor.authorIvey, A.
dc.contributor.authorSouza, A.
dc.contributor.authorPattani, R.
dc.contributor.authoret al.
dc.contributor.conference66th Annual Meeting of the American Society of Hematology (ASH) (7 Dec 2024 - 10 Dec 2024 : San Diego, CA, and online)
dc.date.issued2024
dc.descriptionOral Abstract: 619.Acute Myeloid Leukemias: Disease Burden and Minimal Residual Disease in Prognosis and Treatment
dc.description.abstractAbstract not available
dc.description.statementofresponsibilitySun Loo, Harry Iland, Ing Soo Tiong, David Westerman, Jad Othman, Paula Marlton, Chong Chyn Chua, Duncan Purtill, Hannah Rose, Shaun Fleming, Deepak Singhal, Anoop K Enjeti, William S. Stevenson, Teng Fong Ng, McCulloch Derek, Lachlin Vaughan, Robin Gasiorowski, Adam Ivey, Amanda Souza, Revati Pattani, Natasha S. Anstee, Rachel Koldej, David S. Ritchie, Sanam Loghavi, Naval Daver, Courtney D. DiNardo, Andrew W. Roberts, Carolyn S. Grove, M, John Reynolds, Andrew H Wei
dc.identifier.citationAbstracts of the 66th Annual Meeting of the American Society of Hematology (ASH 2024), as published in Blood, 2024, vol.144, iss.Suppl. 1, pp.223-225
dc.identifier.doi10.1182/blood-2024-202895
dc.identifier.issn0006-4971
dc.identifier.issn1528-0020
dc.identifier.orcidSinghal, D. [0000-0002-2024-2969]
dc.identifier.urihttps://hdl.handle.net/2440/148021
dc.language.isoen
dc.publisherElsevier
dc.relation.grantNHMRC
dc.rights© 2024 American Society of Hematology. Published by Elsevier Inc. All rights reserved.
dc.source.urihttps://www.sciencedirect.com/journal/blood/vol/144/suppl/S1
dc.titleRevumenib As Pre-Emptive Therapy for Measurable Residual Disease in NPM1 mutated or KMT2A-rearranged Acute Myeloid Leukemia: A Domain of the Multi-Arm ALLG AMLM26 Intercept Platform Trial
dc.typeConference item
pubs.publication-statusPublished

Files

Collections

Research Outputs